Targon

Targon is a San Diego-based biotechnology company focused on the discovery and development of next-generation precision oncology therapeutics. The company was founded by the core scientific and executive team behind Turning Point Therapeutics, which was acquired by Bristol Myers Squibb for its innovative macrocyclic platform. Targon leverages advanced structure-based drug design to create highly potent and selective small molecule inhibitors targeting oncogenic drivers. A key differentiator for the company is its focus on developing brain-penetrant molecules capable of crossing the blood-brain barrier to treat primary CNS tumors and brain metastases. Currently in the pre-clinical stage, Targon aims to address the limitations of existing kinase inhibitors, such as off-target toxicities and acquired resistance mutations. The company is backed by leading life science venture capital firms, including ARCH Venture Partners and Foresite Capital.